Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell — AGRAH003  

Persistent Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Clinical Trial

Official title: Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell

Status Completed

Clinical Trial Summary

This is a Phase I/II multicenter study which aims to assess the toxicity profile of Romiplostim in patients with transfusion-dependent thrombocytopenia after allogeneic HSCT.

A total of 24 patients with transfusion-dependent thrombocytopenia after allogeneic HSCT will be included.

The main endpoint is the incidence and severity of adverse events.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Persistent Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
• Thrombocytopenia

• NCT number: NCT01980030
• Study type: Interventional
• Source: Assistance Publique - Hôpitaux de Paris
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 2013
• Completion date: November 2018